OTC
0.06USD
-0.01 (-8.33%)
We have scored 13 news catalysts on Zynex, Inc. (ZYXIQ) over the past 12 months. The biggest single-day move next to one of them came Jan 19, 2026, when ZYXIQ closed +23.8%: “SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Agilon (AGL) Investors of Pending Class Action Lawsuit”. Coverage across the window leans negative (average ticker sentiment −0.93). Most of the impact sits in institutional appeal and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.7M
P/E
—
EPS
—
Beta
1.08
52W range
0.0203-0.7676
Day range
0.05–0.07
Open
0.05
Prev close
0.06
Volume
63.3K
Avg volume
101K
Dividend
0.00
IPO
2004-02-25
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Zynex, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ZYXIQ: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zynex, Inc. is a medical technology company focused on the development, manufacturing, and marketing of electrotherapy devices. These devices are primarily designed to alleviate both chronic and acute pain, and to facilitate muscle activation and rehabilitation. The company's core product offerings include several electrical stimulation devices: NexWave: A versatile, dual-channel device combining interferential current, Transcutaneous Electrical Nerve Stimulation (TENS), and Neuromuscular Electrical Stimulation (NMES) modalities. It is actively promoted to healthcare professionals by the company's field sales team. NeuroMove: An innovative device integrating electromyography with electrical stimulation technology. InWave: An electrical stimulation product specifically engineered for the treatment of female urinary incontinence. E-Wave and M-Wave: Both are specialized NMES devices. Beyond its proprietary devices, Zynex also supplies private-label accessories essential for electrotherapy, such as electrodes for current delivery to the body and batteries to power its products. Furthermore, the company distributes a range of complementary rehabilitation equipment from other manufacturers, including Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, various braces for knee and wrist rehabilitation, and Dynacomp for cold compression therapy. Zynex is also actively engaged in the development of advanced patient monitoring systems. Its pipeline features the Zynex Fluid Monitoring Systems (CM-1500 and the wireless CM-1600), which are non-invasive devices designed to track relative fluid volume changes in adult patients. Other forthcoming monitoring technologies include the NiCO CO-Oximeter, a laser photoplethysmographic device, and the HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company's diverse product portfolio serves critical medical applications, including pain management and control, rehabilitation for stroke and spinal cord injuries, and sophisticated fluid and pulse oximetry monitoring. Zynex primarily sells its products directly to customers through its dedicated sales force, operating predominantly within the United States. Established in 1996, Zynex, Inc. maintains its corporate headquarters in Englewood, Colorado. However, on December 15, 2025, Zynex, Inc. and its affiliated entities filed for Chapter 11 bankruptcy protection, seeking reorganization in the U.S. Bankruptcy Court for the Southern District of Texas.
